Table 1 Dose levels and dose-limiting toxicities (DLTs)

From: Phase I study and preclinical efficacy evaluation of the mTOR inhibitor sirolimus plus gemcitabine in patients with advanced solid tumours

Dose level

Sirolimus (mg per 24 h) orally

Gemcitabine (mg m −2 ) intravenously

DLT/patients

Toxicity

1

2

800

0/3

 

2

2

1000

1/6

Transaminitis G3

2.A

5

800

0/6

 

3

5

1000

2/4

Thrombocytopenia G3

Thrombocytopenia G4

Back to article page